EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer

Robert W Holloway iD, Sarah M Temkin iD, Sarah W Gordon iD, Sunil Gupta, Srinivasa R Jada, Sarfraz Ahmad iD, William P McGuire

Current Oncology · 2025

DOI: 10.3390/curroncol32100532 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Current Oncology, 2025. Verfasst von Robert W Holloway und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Ovarian Neoplasms, Poly I-C, Polylysine. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: OncoQuest Pharmaceuticals, Inc. Edmonton, AB, Canada., OncoQuest Pharmaceuticals, Inc., Edmonton, AB, Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This phase Ib study assessed the safety and compatibility of indirect oregovomab immunization and Toll-like-receptor-3 (TLR3) stimulation with immune adjuvant Hiltonol® (poly-ICLC) and induced clinically relevant CA125-specific anti-tumor immunity in heavily pretreated patients with progressive platinum-resistant ovarian cancer (PROC).

Methods

Patients with elevated serum CA125 level >50 U/mL received four intravenous infusions with 2 mg oregovomab followed by 2 mg Hiltonol® intramuscular 30 min and 48 h post-oregovomab at weeks 0, 3, 6, and 9. At week 12, imaging was performed, and salvage chemotherapy was allowed post-progression per the investigator’s discretion. The Fifth/final oregovomab with Hiltonol® infusion was given at week 16.

Results

Fifteen enrolled patients were analyzed for safety and efficacy. Thirteen (87%) patients completed at least three Hiltonol® infusions with oregovomab, specifically, two cycles (n = 2), three cycles (n = 2), four cycles (n = 3), and five cycles (n = 8). Adverse events included mild fatigue, flu-like symptoms, chills, axillary pain, and injection site discomfort in 13 (87%) patients. Serious adverse events were reported in seven (47%) patients, including Grade 3 hypertension (n = 2), thrombocytopenia (n = 1), and Grade 3 events attributed to underlying disease (n = 4). Ten (67%) patients had disease progression, three (20%) had stable disease, and two were unevaluable. Early humoral response by week 6 was observed in seven of nine (77%) patients, median progression-free survival was 2.7 months (95% confidence interval [CI]: 2.2, 3.3), and median overall survival was 15.0 months (95% CI: 8.2–23.9).

Conclusions

The safety and compatibility of combining oregovomab with Hiltonol® have been demonstrated in this study. The potential to enhance activity of chemotherapy using oregovomab indirect immunization and Hiltonol® stimulation is proposed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalOvarian NeoplasmsPoly I-CPolylysineToll-Like Receptor 3AdultAgedFemaleHumansMiddle AgedAdjuvants, ImmunologicDrug Resistance, NeoplasmCarboxymethylcellulose Sodium

Stichwörter der Autor:innen

CA-125Hiltonol®TLR3 stimulationindirect immunizationoregovomabovarian cancerphase Ib studyplatinum-resistancerecurrent diseasesurvival analysis

Substanzen

Adjuvants, ImmunologicPoly I-Cpoly ICLCPolylysineTLR3 protein, humanToll-Like Receptor 3Carboxymethylcellulose Sodium

Autor:innen und Institutionen

  • Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA.
  • Division of Gynecologic Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • CanariaBio, Inc., Seoul 06044, Gyeonggi-do, Republic of Korea.

ORCID-Profile: Robert W Holloway, Sarah M Temkin, Sarah W Gordon, Sarfraz Ahmad

Förderung

  • OncoQuest Pharmaceuticals, Inc. Edmonton, AB, Canada.
  • OncoQuest Pharmaceuticals, Inc., Edmonton, AB, Canada

Zitieren

APA

Holloway, R. W., Temkin, S. M., Gordon, S. W., Gupta, S., Jada, S. R., Ahmad, S., & McGuire, W. P. (2025). A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer. Current Oncology. https://doi.org/10.3390/curroncol32100532

Vancouver

Holloway RW, Temkin SM, Gordon SW, Gupta S, Jada SR, Ahmad S, et al. A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer. Current Oncology. 2025. doi:10.3390/curroncol32100532

BibTeX
@article{Holloway2025,
  author = {Holloway, Robert W and Temkin, Sarah M and Gordon, Sarah W and Gupta, Sunil and Jada, Srinivasa R and Ahmad, Sarfraz and McGuire, William P},
  title = {A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32100532}
}
Kostenlos starten →